Regeneron Pharmaceuticals, Inc. $REGN Stock Bought by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,865 shares of the biopharmaceutical company’s stock after acquiring an additional 656 shares during the period. Chicago Partners Investment Group LLC’s holdings in Regeneron Pharmaceuticals were worth $2,306,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Covestor Ltd boosted its position in shares of Regeneron Pharmaceuticals by 31.5% in the 3rd quarter. Covestor Ltd now owns 171 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 41 shares in the last quarter. Compass Financial Management LLC boosted its position in Regeneron Pharmaceuticals by 4,526.2% during the third quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock valued at $2,280,000 after purchasing an additional 2,942 shares in the last quarter. Pzena Investment Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $310,000. Rakuten Investment Management Inc. grew its stake in shares of Regeneron Pharmaceuticals by 8.6% during the 3rd quarter. Rakuten Investment Management Inc. now owns 26,693 shares of the biopharmaceutical company’s stock worth $20,033,000 after purchasing an additional 2,113 shares during the period. Finally, Provenance Wealth Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 208.0% during the third quarter. Provenance Wealth Advisors LLC now owns 619 shares of the biopharmaceutical company’s stock worth $469,000 after purchasing an additional 418 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on REGN. Leerink Partners boosted their price target on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the company a “market perform” rating in a research note on Monday, November 2nd. BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. TD Cowen increased their target price on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. Raymond James Financial upped their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, Bank of America upped their target price on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $898.97.

Insider Transactions at Regeneron Pharmaceuticals

In related news, EVP Joseph J. Larosa sold 4,466 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the completion of the sale, the executive vice president owned 38,906 shares of the company’s stock, valued at $37,563,353.94. The trade was a 10.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christine A. Poon sold 7,830 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $969.09, for a total value of $7,587,974.70. Following the completion of the sale, the director directly owned 5,219 shares in the company, valued at approximately $5,057,680.71. The trade was a 60.00% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 28,228 shares of company stock worth $25,985,950. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $904.35 on Friday. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The stock’s fifty day simple moving average is $804.38 and its two-hundred day simple moving average is $742.81. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $991.73. The stock has a market cap of $93.11 billion, a PE ratio of 19.97, a price-to-earnings-growth ratio of 1.51 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same period in the prior year, the company earned $11.83 EPS. The company’s quarterly revenue was up 36.3% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.